{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:28:43Z","timestamp":1793014123332,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Plasma ceramides and sphingomyelins have been independently linked to diabetes risk, glucose and insulin levels, and the risk of several cardiovascular (CVD) outcomes. However, whether individual ceramide and sphingomyelin species contribute to CVD risk among people with type 2 diabetes is uncertain. Our goal was to evaluate associations of 4 ceramide and 4 sphingomyelin species with incident CVD in a longitudinal population-based study among American Indians with diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This analysis included participants with prevalent type 2 diabetes from two cohorts: a prospective cohort of 597 participants in the Strong Heart Family Study (116 incident CVD cases; mean age: 49\u00a0years; average length of follow-up: 14\u00a0years), and a nested case\u2013control sample of 267 participants in the Strong Heart Study (78 cases of CVD and 189 controls; mean age: 61\u00a0years; average time until incident CVD in cases: 3.8\u00a0years). The average onset of diabetes was 7\u00a0years prior to sphingolipid measurement. Sphingolipid species were measured using liquid chromatography and mass spectrometry. Cox regression and logistic regression were used to assess associations of sphingolipid species with incident CVD; results were combined across cohorts using inverse-variance weighted meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 194 cases of incident CVD in the two cohorts. In meta-analysis of the 2 cohort results, higher plasma levels of Cer-16 (ceramide with acylated palmitic acid) were associated with higher CVD risk (HR per two-fold higher Cer-16: 1.85; 95% CI 1.05\u20133.25), and higher plasma levels of sphingomyelin species with a very long chain saturated fatty acid were associated with lower CVD risk (HR per two-fold higher SM-22: 0.48; 95% CI 0.26\u20130.87), although none of the associations met our pre-specified threshold for statistical significance of p\u2009=\u20090.006.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While replication of the findings from the SHS in other populations is warranted, our findings add to a growing body of research suggesting that ceramides, in particular Cer-16, not only are associated with higher diabetes risk, but may also be associated with higher CVD risk after diabetes onset. We also find support for the hypothesis that sphingomyelins with a very long chain saturated fatty acid are associated with lower CVD risk among adults with type 2 diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-022-01596-4","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T15:34:12Z","timestamp":1661873652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Circulating ceramides and sphingomyelins and the risk of incident cardiovascular disease among people with diabetes: the strong heart study"],"prefix":"10.1186","volume":"21","author":[{"given":"Paul N.","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Fretts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew N.","family":"Hoofnagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara V.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G.","family":"Umans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Sitlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Siscovick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena B.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nona","family":"Sotoodehnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozenn N.","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"1596_CR1","unstructured":"Center for Disease Control and Prevention. Diabetes fact sheet: national estimates and general information on diabetes and pre-diabetes in the United States. Atlanta: US Department of Health and Human Services, Center for Disease Control and Prevention; 2011."},{"issue":"9733","key":"1596_CR2","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Emerging Risk Factors Collaboration, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215\u201322.","journal-title":"Lancet"},{"issue":"2","key":"1596_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"24","key":"1596_CR4","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"24","key":"1596_CR5","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560\u201372.","journal-title":"N Engl J Med"},{"key":"1596_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4169","volume":"343","author":"R Boussageon","year":"2011","unstructured":"Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343: d4169.","journal-title":"BMJ"},{"key":"1596_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.569250","volume":"11","author":"BC Field","year":"2020","unstructured":"Field BC, Gordillo R, Scherer PE. The role of ceramides in diabetes and cardiovascular disease regulation of ceramides by adipokines. Front Endocrinol (Lausanne). 2020;11: 569250.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"1596_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2337\/diabetes.54.3.591","volume":"54","author":"SA Summers","year":"2005","unstructured":"Summers SA, Nelson DH. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing\u2019s syndrome. Diabetes. 2005;54(3):591\u2013602.","journal-title":"Diabetes"},{"key":"1596_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100119","volume":"62","author":"AM Fretts","year":"2021","unstructured":"Fretts AM, Jensen PN, Hoofnagle AN, McKnight B, Howard BV, Umans J, et al. Plasma ceramides containing saturated fatty acids are associated with risk of type 2 diabetes. J Lipid Res. 2021;62: 100119.","journal-title":"J Lipid Res"},{"issue":"5","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/jn\/nxz259","volume":"150","author":"AM Fretts","year":"2020","unstructured":"Fretts AM, Jensen PN, Hoofnagle A, McKnight B, Howard BV, Umans J, et al. Plasma ceramide species are associated with diabetes risk in participants of the strong heart study. J Nutr. 2020;150(5):1214\u201322.","journal-title":"J Nutr"},{"issue":"1","key":"1596_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2011.11.001","volume":"51","author":"S Grosch","year":"2012","unstructured":"Grosch S, Schiffmann S, Geisslinger G. Chain length-specific properties of ceramides. Prog Lipid Res. 2012;51(1):50\u201362.","journal-title":"Prog Lipid Res"},{"issue":"5898","key":"1596_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.1158111","volume":"322","author":"X Deng","year":"2008","unstructured":"Deng X, Yin X, Allan R, Lu DD, Maurer CW, Haimovitz-Friedman A, et al. Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of C. elegans. Science. 2008;322(5898):110\u20135.","journal-title":"Science"},{"issue":"5925","key":"1596_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1126\/science.1173278","volume":"324","author":"CM Crowder","year":"2009","unstructured":"Crowder CM. Cell biology. Ceramides\u2014friend or foe in hypoxia? Science. 2009;324(5925):343\u20134.","journal-title":"Science"},{"issue":"22","key":"1596_CR14","doi-asserted-by":"publisher","first-page":"18429","DOI":"10.1074\/jbc.M111.296947","volume":"287","author":"SY Lee","year":"2012","unstructured":"Lee SY, Kim JR, Hu Y, Khan R, Kim SJ, Bharadwaj KG, et al. Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. J Biol Chem. 2012;287(22):18429\u201339.","journal-title":"J Biol Chem"},{"issue":"2","key":"1596_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jacl.2020.01.005","volume":"14","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Dugo C. Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies. J Clin Lipidol. 2020;14(2):176\u201385.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"1596_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005708","volume":"12","author":"RN Lemaitre","year":"2019","unstructured":"Lemaitre RN, Jensen PN, Hoofnagle A, McKnight B, Fretts AM, King IB, et al. Plasma ceramides and sphingomyelins in relation to heart failure risk. Circ Heart Fail. 2019;12(7): e005708.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"1596_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012853","volume":"9","author":"PN Jensen","year":"2020","unstructured":"Jensen PN, Fretts AM, Hoofnagle AN, Sitlani CM, McKnight B, King IB, et al. Plasma ceramides and sphingomyelins in relation to atrial fibrillation risk: the cardiovascular health study. J Am Heart Assoc. 2020;9(4): e012853.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1596_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/db17-1449","volume":"67","author":"RN Lemaitre","year":"2018","unstructured":"Lemaitre RN, Yu C, Hoofnagle A, Hari N, Jensen PN, Fretts AM, et al. Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the strong heart family study. Diabetes. 2018;67(8):1663\u201372.","journal-title":"Diabetes"},{"key":"1596_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebiom.2018.12.046","volume":"41","author":"PN Jensen","year":"2019","unstructured":"Jensen PN, Fretts AM, Yu C, Hoofnagle AN, Umans JG, Howard BV, et al. Circulating sphingolipids, fasting glucose, and impaired fasting glucose: the strong heart family study. EBioMedicine. 2019;41:44\u20139.","journal-title":"EBioMedicine"},{"issue":"6","key":"1596_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/oxfordjournals.aje.a115757","volume":"132","author":"ET Lee","year":"1990","unstructured":"Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol. 1990;132(6):1141\u201355.","journal-title":"Am J Epidemiol"},{"issue":"4","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1093\/aje\/kwf208","volume":"157","author":"KE North","year":"2003","unstructured":"North KE, Howard BV, Welty TK, Best LG, Lee ET, Yeh JL, et al. Genetic and environmental contributions to cardiovascular disease risk in American Indians: the strong heart family study. Am J Epidemiol. 2003;157(4):303\u201314.","journal-title":"Am J Epidemiol"},{"key":"1596_CR22","first-page":"1","volume-title":"Definition, diagnosis, and classification of diabetes mellitus and its complications","author":"World Health Organization","year":"1999","unstructured":"World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999. p. 1\u201359."},{"key":"1596_CR23","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/oxfordjournals.aje.a115757","volume":"132","author":"E Lee","year":"1990","unstructured":"Lee E, Welty T, Fabsitz R, Cowan L, Ngoc A, Oopik A, et al. The strong heart study: a study of cardiovascular disease in american indians: design and methods. Am J Epidemiol. 1990;132:1141\u201355.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"1596_CR24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/db17-1449","volume":"67","author":"RN Lemaitre","year":"2018","unstructured":"Lemaitre RN, Yu C, Hoofnagle A, Hari N, Jensen P, Fretts AM, et al. Circulating sphingolipids, insulin, HOMA-IR and HOMA-B: the strong heart family study. Diabetes. 2018;67(8):1663\u201372.","journal-title":"Diabetes"},{"issue":"1","key":"1596_CR25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/gepi.20435","volume":"34","author":"DY Lin","year":"2010","unstructured":"Lin DY, Zeng D. Meta-analysis of genome-wide association studies: no efficiency gain in using individual participant data. Genet Epidemiol. 2010;34(1):60\u20136.","journal-title":"Genet Epidemiol"},{"issue":"7414","key":"1596_CR26","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"1","key":"1596_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/096228029900800102","volume":"8","author":"JL Schafer","year":"1999","unstructured":"Schafer JL. Multiple imputation: a primer. Stat Methods Med Res. 1999;8(1):3\u201315.","journal-title":"Stat Methods Med Res"},{"key":"1596_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S Van Buuren","year":"2011","unstructured":"Van Buuren S, Groothuis-Oudshoorn K. MICE: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367.","journal-title":"J Stat Softw"},{"issue":"12","key":"1596_CR29","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","volume":"36","author":"AS Havulinna","year":"2016","unstructured":"Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, et al. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. Arterioscler Thromb Vasc Biol. 2016;36(12):2424\u201330.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1596_CR30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41467-022-28496-1","volume":"13","author":"C Wittenbecher","year":"2022","unstructured":"Wittenbecher C, Cuadrat R, Johnston L, Eichelmann F, Jager S, Kuxhaus O, et al. Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology. Nat Commun. 2022;13(1):936.","journal-title":"Nat Commun"},{"issue":"3","key":"1596_CR31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.2337\/dc21-1520","volume":"45","author":"Y Chen","year":"2022","unstructured":"Chen Y, Jia H, Qian X, Wang J, Yu M, Gong Q, et al. Circulating palmitoyl sphingomyelin is associated with cardiovascular disease in individuals with type 2 diabetes: findings from the China Da Qing diabetes study. Diabetes Care. 2022;45(3):666\u201373.","journal-title":"Diabetes Care"},{"key":"1596_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4614-0650-1_2","volume":"721","author":"XC Jiang","year":"2011","unstructured":"Jiang XC, Goldberg IJ, Park TS. Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy. Adv Exp Med Biol. 2011;721:19\u201339.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1596_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2012.08.041","volume":"226","author":"T Hornemann","year":"2013","unstructured":"Hornemann T, Worgall TS. Sphingolipids and atherosclerosis. Atherosclerosis. 2013;226(1):16\u201328.","journal-title":"Atherosclerosis"},{"key":"1596_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/978-1-4614-0650-1_3","volume":"721","author":"M Baranowski","year":"2011","unstructured":"Baranowski M, Gorski J. Heart sphingolipids in health and disease. Adv Exp Med Biol. 2011;721:41\u201356.","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"1596_CR35","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1161\/ATVBAHA.108.173344","volume":"28","author":"CM Devlin","year":"2008","unstructured":"Devlin CM, Leventhal AR, Kuriakose G, Schuchman EH, Williams KJ, Tabas I. Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression. Arterioscler Thromb Vasc Biol. 2008;28(10):1723\u201330.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1596_CR36","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1161\/01.ATV.20.12.2607","volume":"20","author":"S Marathe","year":"2000","unstructured":"Marathe S, Choi Y, Leventhal AR, Tabas I. Sphingomyelinase converts lipoproteins from apolipoprotein E knockout mice into potent inducers of macrophage foam cell formation. Arterioscler Thromb Vasc Biol. 2000;20(12):2607\u201313.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"1596_CR37","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.1074\/jbc.M412348200","volume":"280","author":"MR Hojjati","year":"2005","unstructured":"Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem. 2005;280(11):10284\u20139.","journal-title":"J Biol Chem"},{"issue":"6","key":"1596_CR38","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.chemphyslip.2011.04.013","volume":"164","author":"T Kolter","year":"2011","unstructured":"Kolter T. A view on sphingolipids and disease. Chem Phys Lipids. 2011;164(6):590\u2013606.","journal-title":"Chem Phys Lipids"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01596-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01596-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01596-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T09:17:29Z","timestamp":1700990249000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01596-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01596-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board from each Indian Health Service region and each of the included communities approved the study, and written informed consent was obtained from all participants at each exam.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}